...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC
【24h】

Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC

机译：MCRPC中新治疗方法的耐药性和洞察的分子基础

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Inhibiting androgen receptor (AR) signaling with androgen deprivation therapy (ADT) represents the mainstay of therapy for advanced and metastatic prostate cancer. However, about 20-60% of patients receiving first-line treatment for prostate cancer will relapse, evolving in a more aggressive and lethal form of the disease, the castration-resistant prostate cancer (CRPC), despite the use of ADT. Multiple approved systemic therapies able to prolong survival of patients with metastatic CRPC (mCRPC) exist, but almost invariably, patients treated with these drugs develop primary or acquired resistance. Multiple factors are involved in CRPC treatment resistance and elucidating the mechanisms of action of these factors is a key question and an active area of research. Due to such a complex scenario, treatment personalization is necessary to improve treatment effectiveness and reduce relapse rates in CRPC. In this review, current evidence about the major mechanisms of resistance to the available prostate cancer treatments were examined by introducing insights on new and future therapeutic approaches.
机译：抑制雄激素受体（AR）与雄激素剥夺治疗（ADT）的信号传导代表了先进和转移性前列腺癌的治疗方法。然而，大约20-60％的患者接受前列腺癌的一线治疗患者将复发，以更具侵略性和致命形式的疾病，抵抗症状前列腺癌（CRPC）的发展，尽管使用ADT。通过这些药物治疗的患者存在多种批准的能够延长转移性CRPC（MCRPC）的患者存活的系统疗法，但几乎完全是患者产生初级或获得的抗性。多种因素涉及CRPC处理阻力，并阐明这些因素的作用机制是一个关键问题和活跃的研究领域。由于这种复杂的情景，治疗个性化是改善治疗效果和降低CRPC中复发率的必要条件。在本综述中，通过对新和未来的治疗方法的见解引入了解，研究了关于对可用前列腺癌治疗的主要抵抗力机制的现有证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号